Conditions: Hepatitis C Virus
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 199
Healthy volunteers: no

Brief summary:
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.

Detailed description:
US National Institutes of Health Division of AIDs (DAIDS)

Arms:
arm 1: DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks

Interventions: intervention 1: DCV/ASV/BMS-791325
Intervention descriptions: intervention 1: None

Protocol document: